Affinity proteomics-based non-invasive detection of clinically significant liver disease

BackgroundSince liver disease is often clinically unapparent, non-invasive biomarkers predicting future major adverse liver outcomes (MALO) are urgently needed. Therefore, we assessed the usefulness of a novel, proximity extension assay (PEA)-based high-throughput targeted proteomics method to predict MALOs. MethodsPEA plasma proteomic data (>2900 proteins) and clinical information were accessed from the population-based UK Biobank (UKB) cohort, including >53000 individuals with a median follow-up of >10 years and its subcohorts of obese (>12900) and diabetic (>1600) participants. The validation cohorts comprised 287 subjects with severe alpha1-antitrypsin deficiency (AATD), Pi*ZZ genotype, and 960 people living with HIV (PLHIV), who underwent liver stiffness measurement (LSM) via transient elastography. Selected PEA parameters were compared to routine measurements. Bayes-moderated linear models (age and sex as covariates) assessed the differential abundance. Logistic regression was used to identify and validate a novel prognostic score. ResultsRoutine gamma-glutamyltransferase (GGT) and aspartate aminotransferase (AST) levels strongly correlated with PEA-based measurements (r=0.91 and r=0.68, respectively). Similarly, PEA-based thrombospondin-2 levels strongly correlated with immunoassay-based values (r=0.85). Twenty proteins were consistently associated with future MALOs/increased LSM in all cohorts. UKB cohort was used to develop a novel five-component PEA score that demonstrated superior predictive power (AUROC=0.84) compared to established indices/scores, including AST-to-platelet-ratio index (APRI, AUROC=0.73) and Fibrosis-4 index (FIB4, AUROC=0.72) and its attractive predictive power was sustained in diabetic/obese subcohorts. In PLHIV and AATD validation cohorts, all five components showed gradual increases across fibrosis stages, and PEA score numerically outperformed APRI/FIB4 in predicting significant liver disease. ConclusionOur study identifies a new PEA score consisting of epithelial/hepatic stellate cell markers that demonstrates an attractive discriminative ability in several independent cohorts and different liver disease aetiologies.